Arena Pharmaceuticals (Arena Pharmaceuticals) Debt-to-Equity : 0.06 (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Debt-to-Equity?

Arena Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $5.05 Mil. Arena Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $36.16 Mil. Arena Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2021 was $673.24 Mil. Arena Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2021 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Arena Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ARNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.58 Max: 8.57
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Arena Pharmaceuticals was 8.57. The lowest was 0.00. And the median was 0.58.

ARNA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs ARNA: 0.06

Arena Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Arena Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Debt-to-Equity Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.30

0.09

0.05

0.04

0.06

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.05	0.05	0.06

Competitive Comparison of Arena Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Arena Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Debt-to-Equity falls into.

Arena Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arena Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.052	+	36.159)	/	673.237
	=	0.06

Arena Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.052	+	36.159)	/	673.237
	=	0.06

Arena Pharmaceuticals (NAS:ARNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Arena Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Executives

Amit Munshi	director, officer: President and CEO	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki	officer: EVP, Chief Commercial Officer	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz	officer: Executive VP and CBO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell	officer: EVP, Head of R&D, and CMO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer	officer: EVP & Chief Financial Officer	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt	officer: EVP, General Counsel & Sec	C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind	officer: Executive VP and CFO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121